Scientific Advisory Board

Pamela M. Klein, B.Sc., M.D.

Pamela Klein, M.D.Dr Pamela M Klein completed her medical training at Loyola University in Chicago before working at the U.S. National Cancer Institute. Dr Klein then moved to Genentech where, as Vice President, Development she led the development of a large portfolio of drugs including all the HER (Herceptin, Tarceva, Perjeta), Apoptosis (antibodies and small molecules) and Hematology compounds.  After Genentech Dr Klein was appointed to the position of Chief Medical Officer of Intellikine where she built the clinical development capability and brought multiple early compounds from laboratory to clinic prior to Intellikine being acquired by Milleinium/Takeda. Dr Klein currently serves as an advisor to a range of different biotech and investment companies, with roles on Scientific Advisory Boards and Corporate Boards as well as broader advisory roles.

Allen Ebens, B.Sc., Ph.D.

Allen Ebens, B.Sc., M.D., Ph.D.Dr Allen Ebens completed a PhD at UCLA and completed a Post-Doc at UCSF before joining Exelixis as a scientist in the Discovery Biology group. After more than 5 years with Exelixis Dr Ebens moved to Genentech where over 11 years in the Research Oncology group he worked from concept to clinic across multiple therapeutic platforms including antibodies, small molecule drugs, antibody-drug conjugates, and cell-based therapies. Dr Ebens was recruited from Genentech to establish the oncology research lab at Juno Therapeutics, and he is currently the Senior Director, Immune Oncology at NGM Biopharmaceuticals in South San Francisco.  Over a significant career Dr Ebens’ contributions include advancement of five discovery projects to clinical development and leadership of T cell recruiting bi-specific antibody teams to proof of concept for multiple targets including one clinical candidate.